A multiplexed cell assay in Hepg2 cells for the identification of delta-5, delta-6, and delta-9 desaturase and elongase inhibitors

Journal of Biomolecular Screening

Volumn 15, Issue 2, 2010, Pages 169-176

  Zhang, Lei ^a   Ramtohul, Yeeman ^a   Gagné, Sebastien ^a   Styhler, Angela ^a   Wang, Hao ^a   Guay, Jocelyne ^a   Huang, Zheng ^a  

^a Merck Frosst Center for Therapeutic Research   (United States)

Author keywords

CP 74006; Delta 5 desaturase; Delta 6 desaturase; Delta 9 desaturase; Elongase; Hepg2; SC 26196; Scdl; Sterculic acid

Indexed keywords

ACYL COENZYME A; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; ARACHIDONIC ACID; CARBON 14; CHOLESTEROL ESTER; DOCOSATETRAENOIC ACID; ENZYME; FATTY ACID; FATTY ACYL COENZYME A ELONGASE; ICOSATETRAENOIC ACID; LINOLENIC ACID; LINOLEOYL COENZYME A DESATURASE; LONG CHAIN FATTY ACID; OLEIC ACID; PHOSPHOLIPID; RNA; STEARIC ACID; STERCULIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CHEMICAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; HEPATOMA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLITE; MULTIPLEXED CELL ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ACETYLTRANSFERASES; ACYL COENZYME A; BIOLOGICAL ASSAY; CARBON RADIOISOTOPES; FATTY ACID DESATURASES; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LINOLEOYL-COA DESATURASE; MODELS, BIOLOGICAL; MODELS, CHEMICAL;

EID: 77949341737     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109356208     Document Type: Article

References (32)

1. Angeletti C, de Alaniz MJ: Fatty acid uptake and metabolism in Hep G2 human-hepatoma cells. Mol Cell Biochem 1995;143:99-105.
2. Montanaro MA, Rimoldi OJ, Igal RA, Montenegro S, Tarrés MC, Martinez SM, et al: Hepatic delta.9, delta.6, and delta.5 de saturations in non-insulin-dependent diabetes mellitus eSS rats. Lipids 2003;38: 827-832.
3. Beniert JT Jr, Sprecher H: Studies to determine the role rates of chain elongation and desaturation play in regulating the unsaturated fatty acid composition of rat liver lipids. Biochim Biophys Acta 1975;398:354-363.
4. Dobrzyn A, Ntambi JM: The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot Essent Fatty Acids 2005;73:35-41.
5. Shanklin J, Whittle E, Fox BG: Eight histidine residues are catalytically essential in a membrane-associated iron enzyme, stearoyl-CoA desaturase, and are conserved in alkane hydroxylase and xylene monooxygenase. Biochemistry 1994;33:12787-12794.
6. Yu G, Bjorksten B: Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels. Pediatr Allergy Immunol 1998;9:133-138.
7. Manku MS, Horrobin DF, Morse N, et al. Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy. Prostaglandins Leukot Med 1982;9:615-628.
8. el Boustani S, Causse JE, Descomps B, Monnier L, Mendy F, Ciastes dP: Direct in vivo characterization of delta 5 desaturase activity in humans by deuterium labeling: effect of insulin. Metabolism 1989;38:315-321.
9. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ, etal: Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 2002;43:1899-1907.
10. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A: Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2002;66:467-477.
11. Savransky V, Jun J, Li J, Nanayakkara A, Fonti S, Moser AB, et al: Dyslipidemia Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103:1173-1180.
12. Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger C, Chinn KS, Duffin KL, et al: Novel, selective delta6 or delta.5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther 1998;287:157-166.
13. Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, Zweifel B, et al: Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett 2002;175:157-163.
14. Khoo DE, Fermor B, Miller J, Wood. CB, Apostolov K, Barker W, et al: Manipulation of body fat composition with sterculic acid can inhibit mammary carcinomas in vivo. Br J Cancer 1991;63:97-101.
15. Liu G, Lynch JK, Freeman J, Liu B, Xin Z, Zhao H, et al: Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem 2007;50:3086-3100.
16. Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, et al: Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005;115:1030-1038.
17. Gutiércez-Juárez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, et al: Critical role of stearoyl-CoA desaturase-1 (SCDl) in the onset of dietinduced hepatic insulin resistance. J Clin Invest 2006;116:1686-1695.
18. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, Inoue N, et al: Cnicial role of a long-chain fatty acid elongase, Elov16, in obesity-induced insulin resistance. Nat Med 2007;13:1193-1202.
19. Dixon JL, Ginsberg HN: Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res 1993;34:167-179.
20. Li CS, Belair L, Quay J, Murgasva R, Sturkenboom W, Ramtohul YK, et al. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett 2009;19:5214-5217.
21. Rise P, Ghezzi S, Priori I, Galli C: Differential modulation by simvastatin of the metabolic pathways in the n-9, n-6 and n-3 fatty acid series, in human monocytic and hepatocytic cell lines. Biochem Pharmacol 2005;69:1095-1100.
22. Choi Y, Park Y, Pariza MW, Ntambi JM: Regulation of stearoyl-CoA. desaturase activity by the trans-10,cis-12 isomer of conjugated linoleic acid in HepG2 cells. Biochem Biophys Res Commun 2001;284:689-693.
23. Wang J, Yu L, Schmidt RE, Su C, HuangX, Gould K, etal: Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem Biophys Res Commun 2005;332:735-742.
24. Elovson J: Immediate fate of albumin-bound [I-14C] stearic acid following its intraportal injection into carbohydrate refed rats: early course of desaturation and esterification in the liver. Biochim Biophys Acta 1965;106:480-494.
25. Enoch HG, Cátala A, Strittmatter P: Mechanism of rat liver microsomal stearyl-CoA desaturase: studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J Biol Chem 1976;251:5095-5103.
26. Jeffcoat R, Pollard MR: Studies on the inhibition of the desaturases by cyclopropenoid fatty acids. Lipids 1977;12:480-485.
27. Gomez FE, Bauman DE, Ntambi JM, Fox BG: Effects of sterculic acid on stearoyl-CoA desaturase in differentiating 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003;300:316-326.
28. Dillon R, Greig MJ, Bliat BG: Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity. Anal Chim Acta 2008;627:99-104.
29. Obukowicz MG, Raz A, Pyia PD, Rico JG, Wendung JM, Needleman P: Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem Pharmacol 1998;55:1045-1058.
30. Harmon SD, Kaduce TL, Manuel TD, Spector AA: Effect of the delta.6desaturase inhibitor SC-26196 on PUFA metabolism in human cells. Lipids 2003;38:469-476.
31. Wang Y, Botolin D, Christian B, Busik J, Xu J, Jump DB: Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 2005;46:706-715.
32. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.